AIM AIM ImmunoTech Inc
Price (delayed)
$0.125
Market cap
$9.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.31
Enterprise value
$10.28M
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease
Highlights
The company's EPS rose by 48% YoY and by 34% QoQ
The net income has increased by 40% YoY and by 28% from the previous quarter
AIM ImmunoTech's equity has shrunk by 145% QoQ and by 113% YoY
AIM ImmunoTech's quick ratio has plunged by 72% YoY and by 41% from the previous quarter
Key stats
What are the main financial stats of AIM
Market
Valuations
Earnings
Shares outstanding
72.29M
Market cap
$9.04M
Enterprise value
$10.28M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
41.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.45
Revenue
$170,000
Gross profit
$139,000
Operating income
-$19.77M
Net income
-$17.32M
EBIT
-$16.74M
EBITDA
-$16.19M
Free cash flow
-$14.91M
Per share
Balance sheet
Liquidity
EPS
-$0.31
EPS diluted
-$0.31
Free cash flow per share
-$0.27
Book value per share
-$0.02
Revenue per share
$0
TBVPS
$0.11
Total assets
$8.61M
Total liabilities
$9.93M
Debt
$2.94M
Equity
-$1.32M
Working capital
-$5.36M
Debt to equity
-2.22
Current ratio
0.44
Quick ratio
0.42
Net debt/EBITDA
-0.08
Margins
Efficiency
Dividend
EBITDA margin
-9,520.6%
Gross margin
81.8%
Net margin
-10,188.2%
Operating margin
-11,630.6%
Return on assets
-128.1%
Return on equity
-553.4%
Return on invested capital
-712%
Return on capital employed
N/A
Return on sales
-9,844.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AIM stock price
How has the AIM ImmunoTech stock price performed over time
Intraday
2.21%
1 week
-9.22%
1 month
-7.41%
1 year
-74.5%
YTD
-36.87%
QTD
2.21%
Financial performance
How have AIM ImmunoTech's revenue and profit performed over time
Revenue
$170,000
Gross profit
$139,000
Operating income
-$19.77M
Net income
-$17.32M
Gross margin
81.8%
Net margin
-10,188.2%
The net income has increased by 40% YoY and by 28% from the previous quarter
The operating income has grown by 38% YoY and by 29% from the previous quarter
The net margin rose by 29% year-on-year and by 19% since the previous quarter
The company's operating margin rose by 26% YoY and by 21% QoQ
Growth
What is AIM ImmunoTech's growth rate over time
Valuation
What is AIM ImmunoTech stock price valuation
P/E
N/A
P/B
N/A
P/S
41.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.45
The company's EPS rose by 48% YoY and by 34% QoQ
AIM ImmunoTech's equity has shrunk by 145% QoQ and by 113% YoY
AIM's P/S is 86% below its 5-year quarterly average of 298.2 and 56% below its last 4 quarters average of 91.5
AIM ImmunoTech's revenue has decreased by 16% YoY and by 11% QoQ
Efficiency
How efficient is AIM ImmunoTech business performance
The return on invested capital has dropped by 83% year-on-year and by 17% since the previous quarter
The ROE has contracted by 39% from the previous quarter
The company's return on sales rose by 31% YoY and by 20% QoQ
AIM's ROA is down by 31% YoY but it is up by 13% QoQ
Dividends
What is AIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AIM.
Financial health
How did AIM ImmunoTech financials performed over time
The total assets is 13% smaller than the total liabilities
AIM's current ratio has dropped by 74% year-on-year and by 41% since the previous quarter
AIM ImmunoTech's quick ratio has plunged by 72% YoY and by 41% from the previous quarter
AIM ImmunoTech's equity has shrunk by 145% QoQ and by 113% YoY
The debt has declined by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.